Antibodies to Watch in 2021 (Webinar)

The COVID-19 pandemic has presented many challenges to the biopharmaceutical industry. Initiating programs to discover and develop new antibodies that targeted SARS-CoV-2 was critical, but at the same time, programs bringing existing investigational therapies through late-stage clinical studies and regulatory review also needed to be maintained.

Dr. Janice Reichert (The Antibody Society) will provide an update on antibody therapeutics approved in the US and European Union during 2020, those that may be approved by the end of 2021, and those that might enter regulatory review in the US or EU soon. She will also discuss current and potential emergency use authorizations for anti-SARS-CoV-2 antibodies.

Dr. Nick Hutchinson (FUJIFILM Diosynth Biotechnologies) will discuss how the pandemic has driven scientists and engineers to find new ways to leverage antibody production capacity most effectively in order to meet the need for rapid early phase development, as well as high-demand commercial manufacturing and what this may mean for antibody manufacturing strategies in the future.

Seminar Information
Date Presented:
December 03, 2020 11:00 AM Eastern
Length:
1 hour
Registration Fee:
Free
Registration for this event is closed
Antibodies to Watch in 2021 (Webinar)

The COVID-19 pandemic has presented many challenges to the biopharmaceutical industry. Initiating programs to discover and develop new antibodies that targeted SARS-CoV-2 was critical, but at the same time, programs bringing existing investigational therapies through late-stage clinical studies and regulatory review also needed to be maintained.

Dr. Janice Reichert (The Antibody Society) will provide an update on antibody therapeutics approved in the US and European Union during 2020, those that may be approved by the end of 2021, and those that might enter regulatory review in the US or EU soon. She will also discuss current and potential emergency use authorizations for anti-SARS-CoV-2 antibodies.

Dr. Nick Hutchinson (FUJIFILM Diosynth Biotechnologies) will discuss how the pandemic has driven scientists and engineers to find new ways to leverage antibody production capacity most effectively in order to meet the need for rapid early phase development, as well as high-demand commercial manufacturing and what this may mean for antibody manufacturing strategies in the future.

Speaker Information
Nick Hutchinson  [ view bio ]
Janice Reichert  [ view bio ]
Individual topic purchase: Selected